Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

Drug Resistance Updates

Volumn 12, Issue 4-5, 2009, Pages 103-113

  Konopleva, Marina ^a   Tabe, Yoko ^b   Zeng, Zhihong ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AMD3100; Bone marrow microenvironment; CXCR4; Drug resistance; Leukemia; Molecular targeted therapy; Stem cell niche

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; GEMCITABINE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; INTEGRIN LINKED KINASE; LENALIDOMIDE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLERIXAFOR; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW CELL; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL COMMUNICATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 70349735988     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2009.06.001     Document Type: Article

References (130)

1. Abkowitz J.L., Robinson A.E., Kale S., Long M.W., and Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102 (2003) 1249-1253
2. Adams G.B., Chabner K.T., Alley I.R., Olson D.P., Szczepiorkowski Z.M., Poznansky M.C., Kos C.H., Pollak M.R., Brown E.M., and Scadden D.T. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439 (2006) 599-603
3. Adams G.B., and Scadden D.T. The hematopoietic stem cell in its place. Nat. Immunol. 7 (2006) 333-337
4. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., Ito K., Koh G.Y., and Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118 (2004) 149-161
5. Arora A., and Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315 (2005) 971-979
6. + stem/progenitor cells to bone marrow. Blood 103 (2004) 2981-2989
7. Blade J., Cibeira M.T., and Rosinol L. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol. 44 (2005) 440-448
8. Blau O., Hofmann W.K., Baldus C.D., Thiel G., Serbent V., Schümann E., Thiel E., and Blau I.W. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 35 (2007) 221-229
9. Bradstock K.F., Makrynikola V., Bianchi A., Shen W., Hewson J., and Gottlieb D.J. Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 14 (2000) 882-888
10. Braun B.S., and Shannon K. Targeting Ras in myeloid leukemias. Clin. Cancer Res. 14 (2008) 2249-2252
11. Broxmeyer H.E., Cooper S., Kohli L., Hangoc G., Lee Y., Mantel C., Clapp D.W., and Kim C.H. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J. Immunol. 170 (2003) 421-429
12. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201 (2005) 1307-1318
13. Burger M., Hartmann T., Krome M., Rawluk J., Tamamura H., Fujii N., Kipps T.J., and Burger J.A. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106 (2005) 1824-1830
14. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 (2003) 841-846
15. Cancelas J.A., and Williams D.A. Stem cell mobilization by beta2-agonists. Nat. Med. 12 (2006) 278-279
16. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
17. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 25 (2007) 884-896
18. Clarke D.J. Proteolysis and the cell cycle. Cell Cycle 1 (2002) 233-234
19. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., and Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322 (2008) 1861-1865
20. Crazzolara R., Kreczy A., Mann G., Heitger A., Eibl G., Fink F.M., Mohle R., and Meister B. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 115 (2001) 545-553
21. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4082-4085
22. Dazzi F., Ramasamy R., Glennie S., Jones S.P., and Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 20 (2006) 161-171
23. Di Raimondo F., Palumbo G.A., Molica S., and Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 106 (2001) 177-183
24. Dialynas D.P., Shao L., Billman G.F., and Yu J. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood. Stem Cells 19 (2001) 443-452
25. Dias S., Shmelkov S.V., Lam G., and Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99 (2002) 2532-2540
26. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., San Miguel J., Hellmann A., Facon T., Foa R., Corso A., Masliak Z., Olesnyckyj M., Yu Z., Patin J., Zeldis J.B., Knight R.D., and Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357 (2007) 2123-2132
27. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
28. Fiedler W., Serve H., Döhner H., Schwittay M., Ottmann O.G., O'Farrell A.M., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
29. Fiegl M., Samudio I., Clise-Dwyer K., Burks J.K., Mnjoyan Z., and Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113 (2009) 1504-1512
30. Garcia-Gila M., Lopez-Martin E.M., and Garcia-Pardo A. Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors. Clin. Exp. Immunol. 127 (2002) 455-462
31. BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res. 65 (2005) 2676-2683
32. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20 (2002) 1692-1703
33. Holyoake T.L., Jiang X., Drummond M.W., Eaves A.C., and Eaves C.J. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16 (2002) 549-558
34. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95 (2000) 309-313
35. Ishibe N., Albitar M., Jilani I.B., Goldin L.R., Marti G.E., and Caporaso N.E. CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. Blood 100 (2002) 1100-1101
36. Iwamoto S., Mihara K., Downing J.R., Pui C.H., and Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117 (2007) 1049-1057
37. Jazin E.E., Soderstrom S., Ebendal T., and Larhammar D. Embryonic expression of the mRNA for the rat homologue of the fusin/CXCR-4 HIV-1 co-receptor. J. Neuroimmunol. 79 (1997) 148-154
38. Jensen P.O., Mortensen B.T., Hodgkiss R.J., Iversen P.O., Christensen I.J., Helledie N., and Larsen J.K. Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif. 33 (2000) 381-395
39. Jesenberger V., and Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 3 (2002) 112-121
40. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006) 1167-1174
41. Jin L., Tabe Y., Konoplev S., Xu Y., Leysath C.E., Lu H., Kimura S., Ohsaka A., Rios M.B., Calvert L., Kantarjian H., Andreeff M., and Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 7 (2008) 48-58
42. Jones D.L., and Wagers A.J. No place like home: anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell. Biol. 9 (2008) 11-21
43. Juarez J., Bradstock K.F., Gottlieb D.J., and Bendall L.J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17 (2003) 1294-1300
44. Karp J.E., Gojo I., Pili R., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabiofuranosylcytosine, mitoxantrone and bevacizumab. Clin. Cancer Res. 10 (2004) 3577-3585
45. Kiel M.J., Yilmaz O.H., Iwashita T., Terhorst C., and Morrison S.J. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121 (2005) 1109-1121
46. Kiel M.J., Radice G.L., and Morrison S.J. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 1 (2007) 204-217
47. Kini A.R., Peterson L.A., Tallman M.S., and Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97 (2001) 3919-3924
48. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., and Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther. 7 (2008) 90-100
49. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., Tesio M., Samstein R.M., Goichberg P., Spiegel A., Elson A., and Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12 (2006) 657-664
50. Konoplev S., Rassidakis G.Z., Estey E., Kantarjian H., Liakou C.I., Huang X., Xiao L., Andreeff M., Konopleva M., and Medeiros L.J. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109 (2007) 1152-1156
51. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., and Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16 (2002) 1713-1724
52. Koomagi R., Zintl F., Sauerbrey A., and Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin. Cancer Res. 7 (2001) 3381-3384
53. Kopp H.G., Avecilla S.T., Hooper A.T., and Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20 (2005) 349-356
54. Korkolopoulou P., Apostolidou E., Pavlopoulos P.M., Kavantzas N., Vyniou N., Thymara, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia 15 (2001) 1369-1376
55. Lapidot T., Dar A., and Kollet O. How do stem cells find their way home?. Blood 106 (2005) 1901-1910
56. Lataillade J.J., Clay D., Dupuy C., Rigal S., Jasmin C., Bourin P., and Bousse-Kerdiles M.C. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 95 (2000) 756-768
57. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., and Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 2353-2358
58. Li L., and Neaves W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66 (2006) 4553-4557
59. Liesveld J.L., Jordan C.T., and Phillips II G.L. The hematopoietic stem cell in myelodysplasia. Stem Cells 22 (2004) 590-599
60. Litz J., and Krystal G.W. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol. Cancer Ther. 5 (2006) 1415-1422
61. Liu F., Wang P., Jiang X., Tan G., Qiao H., Jiang H., Krissansen G.W., and Sun X. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci. 99 (2008) 2055-2061
62. Loetscher M., Geiser T., O'Reilly T., Zwahlen R., Baggiolini M., and Moser B. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol. Chem. 269 (1994) 232-237
63. Lopez-Villar O., Garcia J.L., Sanchez-Guijo F.M., Robledo C., Villaron E.M., Hernández-Campo P., et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 23 (2009) 664-672
64. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., Bronson R.T., and Springer T.A. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9448-9453
65. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., and Deeg H.J. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2865-2870
66. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9 (2003) 1158-1165
67. Matsuoka S., Oike Y., Onoyama I., Iwama A., Arai F., Takubo K., et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 22 (2008) 986-991
68. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., and Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (2002) 3767-3775
69. McConkey D.J., and Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updates 11 (2008) 164-179
70. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
71. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., and Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42 (2006) 1564-1573
72. Miyake K., Medina K., Ishihara K., Kimoto M., Auerbach R., and Kincade P.W. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J. Cell. Biol. 114 (1991) 557-565
73. Mohle R., Failenschmid C., Bautz F., and Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 13 (1999) 1954-1959
74. Mohle R., Shittenhelm M., Faienschmid C., Bautz F., Kratz-Albers K., Serve H., Brugger W., and Kanz L. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br. J. Haematol. 110 (2000) 563-572
75. Morrison S.J., and Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell132 (2008) 598-611
76. Mortensen B.T., Jensen P.O., Helledie N., Iversen P.O., Ralfkiaer E., Larsen J.K., and Madsen M.T. Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br. J. Haematol. 102 (1998) 458-464
77. Mudry R.E., Fortney J.E., York T., Hall B.M., and Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 96 (2000) 1926-1932
78. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
79. Naveiras O., and Daley G.Q. Stem cells and their niche: a matter of fate. Cell. Mol. Life Sci. 63 (2006) 760-766
80. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood 113 (2009) 6206-6214
81. Nilsson S.K., Johnston H.M., and Coverdale J.A. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97 (2001) 2293-2299
82. Nilsson S.K., Johnston H.M., Whitty G.A., Williams B., Webb R.J., Denhardt D.T., et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106 (2005) 1232-1239
83. Ninomiya M., Abe A., Katsumi A., Xu J., Ito M., Arai F., et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 21 (2007) 136-142
84. Parmar K., Mauch P., Vergilio J.A., Sackstein R., and Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 5431-5436
85. Passegue E., Wagers A.J., Giuriato S., Anderson W.C., and Weissman I.L. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202 (2005) 1599-1611
86. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer 38 (2002) S3-S10
87. + cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 20 (2002) 259-266
88. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., and Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150 (1997) 815-821
89. Perry J.M., and Li L. Disrupting the stem cell niche: good seeds in bad soil. Cell 129 (2007) 1045-1047
90. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., Ferrucci P.F., et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer 81 (1999) 1398-1401
91. Ptasznik A., Urbanowska E., Chinta S., Costa M.A., Katz B.A., Stanislaus M.A., et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 196 (2002) 667-678
92. Qiang Y.W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., Barlogie B., and Shaughnessy Jr. J.D. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112 (2008) 196-207
93. Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G., Anderson, K.C., 2009. Multiple myeloma. Lancet doi:10.1016/S0140-6736(09)60221-x.
94. Rajkumar S.V., Leong T., Roche P.C., Fonseca R., Dispenzieri A., Lacy M.Q., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin. Cancer Res. 6 (2000) 3111-3116
95. Ramasamy R., Lam E.W., Soeiro I., Tisato V., Bonnet D., and Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21 (2007) 304-310
96. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
97. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57 (2006) 33-47
98. Roccaro A.M., Hideshima T., Raje N., Kumar S., Ishitsuka K., Yasui H., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66 (2006) 184-191
99. Rombouts E.J., Pavic B., Löwenberg B., and Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104 (2004) 550-557
100. Rupec R.A., Jundt F., Rebholz B., Eckelt B., Weindl G., Herzinger T., et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity 22 (2005) 479-491
101. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131 (2007) 324-336
102. Salgia R., Quackenbush E., Lin J., Souchkova N., Sattler M., Ewaniuk D.S., et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 94 (1999) 4233-4246
103. Schmidt-Arras D., Schwable J., Bohmer F.D., and Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr. Pharm. Des. 10 (2004) 1867-1883
104. Shen W., Bendall L.J., Gottlieb D.J., and Bradstock K.F. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp. Hematol. 29 (2001) 1439-1447
105. Shojaei F., and Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to-anti-angiogenic therapies. Drug Resist. Updates 11 (2008) 219-230
106. Sipkins D.A., Wei X., Wu J.W., Runnels J.M., Côté D., Means T.K., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435 (2005) 969-973
107. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
108. Strieter R.M. Masters of angiogenesis. Nat. Med. 11 (2005) 925-927
109. Sugiyama T., Kohara H., Noda M., and Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25 (2006) 977-988
110. Tabe Y., Jin L., Tsutsumi-Ishii Y., Xu Y., McQueen T., Priebe W., Mills G.B., Ohsaka A., Nagaoka I., Andreeff M., and Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 67 (2007) 684-694
111. Trisciuoglio D., Iervolino A., Zupi G., and Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol. Biol. Cell 16 (2005) 4153-4162
112. Turley E.A., Noble P.W., and Bourguignon L.Y. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277 (2002) 4589-4592
113. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., Albini A., Bussolino F., and Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93 (1999) 3064-3073
114. Veschini L., Belloni D., Foglieni C., Cangi M.G., Ferrarini M., Caligaris-Cappio F., and Ferrero E. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109 (2007) 2565-2570
115. Voermans C., van Heese W.P., de Jong I., Gerritsen W.R., and van der Schoot C.E. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 16 (2002) 650-657
116. Walkley C.R., Shea J.M., Sims N.A., Purton L.E., and Orkin S.H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129 (2007) 1081-1095
117. Walkley C.R., Olsen G.H., Dworkin S., Fabb S.A., Swann J., McArthur G.A., et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129 (2007) 1097-1110
118. Wang M., Dimopoulos M.A., Chen C., Cibeira M.T., Attal M., Spencer A., Rajkumar S.V., Yu Z., Olesnyckyj M., Zeldis J.B., Knight R.D., and Weber D.M. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112 (2008) 4445-4451
119. Warner J.K., Wang J.C., Hope K.J., Jin L., and Dick J.E. Concepts of human leukemic development. Oncogene 23 (2004) 7164-7177
120. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., Siegel D., Borrello I., Rajkumar S.V., Chanan-Khan A.A., Lonial S., Yu Z., Patin J., Olesnyckyj M., Zeldis J.B., Knight R.D., and Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357 (2007) 2133-2142
121. Weisberg E., Barrett R., Liu Q., Stone R., Gray N., and Griffin J.D. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updates 12 (2009) 81-89
122. Wellmann S., Guschmann M., Griethe W., Eckert C., von Stackelberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 18 (2004) 926-933
123. Wight T.N., Kinsella M.G., Keating A., and Singer J.W. Proteoglycans in human long-term bone marrow cultures: biochemical and ultrastructural analyses. Blood 67 (1986) 1333-1343
124. Xie Y., Yin T., Wiegraebe W., He X.C., Miller D., Stark D., et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457 (2009) 97-101
125. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., and Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
126. Zahiragic L., Schliemann C., Bieker R., et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21 (2007) 1310-1312
127. Zeng Z., Shi Y.X., Samudio I.J., Wang R.Y., Ling X., Frolova O., Levis M., Rubin J.B., Negrin R.R., Estey E.H., Konoplev S., Andreeff M., and Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113 (2009) 6215-6224
128. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
129. Zhang J., Wang J., Liu Y., Sidik H., Young K.H., Lodish H.F., and Fleming M.D. Oncogenic K-ras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113 (2009) 1304-1314
130. Zuckerman K.S., and Wicha M.S. Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures. Blood 61 (1983) 540-547